ASTRO | Jotup

Medical Journal: Image-Guided Superficial Radiation Therapy Is Superior to Superficial Radiation Therapy Without Guidance

Retrieved on:

Dienstag, Februar 20, 2024

BURR RIDGE, Ill., Feb. 20, 2024 /PRNewswire/ -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT) for the treatment of nonmelanoma skin cancer, presented to dermatology patients as the GentleCure™ experience, announced the publication of research, "Image guidance improves freedom from recurrence in superficial radiation therapy for non-melanoma skin cancer," in Advances in Radiation Oncology, a peer-reviewed journal from the American Society for Radiation Oncology (ASTRO).

Key Points:

It shows definitively that the new technology is superior, and represents a seminal moment in the care of skin cancer patients using radiation.
This study is the first to rigorously compare SRT to IGSRT, and it covers all the data that exists on IGSRT.
Superficial radiation therapy was developed over 100 years ago ( here ) and was the standard therapy for nonmelanoma skin cancer until Mohs micrographic surgery emerged in the 1930's ( here ).
IGSRT and the GentleCure experience will be showcased at the upcoming American Academy of Dermatology annual meeting in San Diego, at booth 3555.

New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma

Retrieved on:

Donnerstag, Januar 18, 2024

While ART can benefit some patients, selecting patients based upon clinicopathologic factors alone can lead to overtreatment of certain patients who may not experience disease progression.

Key Points:

While ART can benefit some patients, selecting patients based upon clinicopathologic factors alone can lead to overtreatment of certain patients who may not experience disease progression.
In the study, normalized medical claims data identified 22,917 Medicare-eligible SCC patients in the United States who received ART in the 12 months ending June 2022.
Results from the study indicate that using the DecisionDx-SCC test to guide decisions about ART could result in net Medicare healthcare savings of up to approximately $972 million annually.
This outcome is based on the distribution of DecisionDx-SCC test results reported in previous studies, with cost reductions attributed to avoiding ART in patients with a DecisionDx-SCC low-risk, Class 1 test result and low rates of disease progression.

Online Video Remains the Growth Engine of Content Investment with Local Content Still Key to Acquiring Subscribers

Retrieved on:

Montag, Dezember 11, 2023

Ex-China, online video revenues in Asia Pacific were expected to hit US$46 billion in 2028, up from US$29 billion this year.

Key Points:

Ex-China, online video revenues in Asia Pacific were expected to hit US$46 billion in 2028, up from US$29 billion this year.
In terms of content trends and investment, although pay TV remained the largest vertical, online video was the growth engine of video content investment, with local and Asian content leading premium VOD viewership with the highest reach.
Hence local content remained key to acquiring subscribers in the region, and constantly over-indexing with new users.
A strong focus on content closed off the Summit, with panellists agreeing that Asian content could not be lumped together.

Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights

Retrieved on:

Dienstag, November 14, 2023

Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.

Key Points:

Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.
Third quarter 2023 revenue was the highest since the second quarter of 2022, with a return to growth over the third quarter of 2022.
Total operating expenses for the quarter ended September 30, 2023 were $11.3 million, compared to $4.6 million for the same period in 2022, an increase of 144%.
Cash and cash equivalents as of September 30, 2023 was $18.0 million as compared to $43.9 million on December 31, 2022.

Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

Retrieved on:

Dienstag, November 14, 2023

MALVERN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended September 30, 2023 and provided recent corporate updates.

Key Points:

The Company is exploring potential strategic alternatives, as it is not feasible to conduct an additional trial with the Company’s current resources.
Research and development expenses were $6.1 million in the third quarter of 2023, compared to $8.1 million for the same period in 2022.
General and administrative expenses were $5.0 million in the third quarter of 2023, compared to $4.9 million for the same period in 2022.
As of September 30, 2023, Galera had cash, cash equivalents and short-term investments of $28.4 million.

American Shared Hospital Services Reports Third Quarter 2023 Financial Results

Retrieved on:

Montag, November 13, 2023

SAN FRANCISCO, CA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and services, today announced financial results for the third quarter ended September 30, 2023.

Key Points:

Operating income for the third quarter of 2023 was $90,000 compared to operating income of $448,000 in the third quarter of 2022.
Adjusted EBITDA, a non-GAAP financial measure, was $1,669,000 for the third quarter of 2023, compared to $1,966,000 for the third quarter of 2022.
Net income attributable to American Shared Hospital Services in the third quarter of 2023 was $118,000, or $0.02 per diluted share, compared to net income of $316,000, or $0.05 per diluted share, for the third quarter of 2022.
Adjusted EBITDA, a non-GAAP financial measure, was $1,669,000 for the third quarter of 2023, compared to $1,966,000 for the third quarter of 2022.

Fuse Oncology Announces Strategic Collaboration with Radiation Oncology Leader

Retrieved on:

Donnerstag, Dezember 14, 2023

BOONE, N.C., Dec. 14, 2023 /PRNewswire/ -- Fuse Oncology (Fuse), a leading innovator in cutting-edge radiation oncology solutions, announced today a strategic collaboration with the University of Michigan , a recognized leader in radiation oncology.

Key Points:

BOONE, N.C., Dec. 14, 2023 /PRNewswire/ -- Fuse Oncology (Fuse), a leading innovator in cutting-edge radiation oncology solutions, announced today a strategic collaboration with the University of Michigan , a recognized leader in radiation oncology.
"Being an integral part of this transformative venture is truly inspiring," said Martha Matuszak, PhD, director of the physics division in U-M's Department of Radiation Oncology.
Fuse's collaboration with U-M and Cone Health combines the expertise and resources of two radiation oncology powerhouses—sparking a new wave of innovation and product development.
We are experiencing an exciting venture energy in the industry that makes this so rewarding," said Benjamin (BJ) Sintay, Executive Director of Radiation Oncology at Cone Health & Chief Innovation Officer at Fuse Oncology.

World's leading ASTRO N7s ZBB-TF TOPCon products to benefit DG & residential markets worldwide

Retrieved on:

Montag, November 20, 2023

Topcon, ASTRO, LID, Collection, Multimedia, Gamer, ZBB, TF, Silicon, Certification, PV, Cell, Renewable energy, Sewage treatment

HANGZHOU, China, Nov. 20, 2023 /PRNewswire/ -- Specially designed for distributed generation (DG) and residential markets worldwide, Astronergy unveiled the world's first ZBB (Zero BusBar Interconnection Technology) - TF (Tiling Film) manufacturing techs powered ASTRO N7s n-type TOPCon PV module products, which has the top conversion efficiency of over 23% among mainstream DG & residential products.

Key Points:

HANGZHOU, China, Nov. 20, 2023 /PRNewswire/ -- Specially designed for distributed generation (DG) and residential markets worldwide, Astronergy unveiled the world's first ZBB (Zero BusBar Interconnection Technology) - TF (Tiling Film) manufacturing techs powered ASTRO N7s n-type TOPCon PV module products, which has the top conversion efficiency of over 23% among mainstream DG & residential products.
To eliminate cell gaps to increase module efficiency significantly, Astronergy exquisitely applied TF tech manufacturing tech at the ASTRO N7s product's 54 pieces of ZBB tech-manufactured TOPCon cells, and high-density encapsulation on the module products.
With these techs, the products will become much more environmentally friendly and more sustainable, while also having better bending resistance performance.
Ready to be massively produced, ASTRO N7s ZBB-TF PV modules are expected to benefit more areas for generating green and sustainable powers.

World's leading ASTRO N7s ZBB-TF TOPCon products to benefit DG & residential markets worldwide

Retrieved on:

Montag, November 20, 2023

Topcon, ASTRO, LID, Collection, Gamer, ZBB, TF, Silicon, Certification, PV, Cell, Renewable energy, Sewage treatment

HANGZHOU, China, Nov. 20, 2023 /PRNewswire/ -- Specially designed for distributed generation (DG) and residential markets worldwide, Astronergy unveiled the world's first ZBB (Zero BusBar Interconnection Technology) - TF (Tiling Film) manufacturing techs powered ASTRO N7s n-type TOPCon PV module products, which has the top conversion efficiency of over 23% among mainstream DG & residential products.

Key Points:

HANGZHOU, China, Nov. 20, 2023 /PRNewswire/ -- Specially designed for distributed generation (DG) and residential markets worldwide, Astronergy unveiled the world's first ZBB (Zero BusBar Interconnection Technology) - TF (Tiling Film) manufacturing techs powered ASTRO N7s n-type TOPCon PV module products, which has the top conversion efficiency of over 23% among mainstream DG & residential products.
To eliminate cell gaps to increase module efficiency significantly, Astronergy exquisitely applied TF tech manufacturing tech at the ASTRO N7s product's 54 pieces of ZBB tech-manufactured TOPCon cells, and high-density encapsulation on the module products.
With these techs, the products will become much more environmentally friendly and more sustainable, while also having better bending resistance performance.
Ready to be massively produced, ASTRO N7s ZBB-TF PV modules are expected to benefit more areas for generating green and sustainable powers.

With larger wafers, Astronergy ASTRO N7 products to drop PV power station costs to lower level

Retrieved on:

Dienstag, November 14, 2023

Topcon, ASTRO, LID, Multimedia, M10, N7, Water, Silicon, PV, Cell, BOS, Renewable energy

As an extension of the company's ASTRO N7 series products, the 66-cell TOPCon products are still manufactured based on Astronergy's independently developed TOPCon 3.0 cell tech and advanced SMBB cell processing tech, which could enable the cells an average efficiency of over 25.7%.

Key Points:

As an extension of the company's ASTRO N7 series products, the 66-cell TOPCon products are still manufactured based on Astronergy's independently developed TOPCon 3.0 cell tech and advanced SMBB cell processing tech, which could enable the cells an average efficiency of over 25.7%.
One of the main differences that make the product unique is the 210mm n-type rectangular silicon wafers the products use.
For utility-scale solar system customers, ASTRO N7 66-cell product has lower BOS costs compared to the 182mm square wafer modules, and the low voltage characteristics of the product could bring benefits to the solar system design.
As a top 6 PV module supplier worldwide at global shipment, Astronergy is acting as a tech promoter and market insighter who dives and develops better and adaptable products for customers.